Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:ETHZ NASDAQ:LIXT NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$1.18-6.3%$1.82$1.16▼$9.22$30.15M0.67465,919 shs93,394 shsETHZFlag Ship Acquisition$5.73+1.1%$5.25$0.70▼$17.46$108.94M1.176.44 million shs144,402 shsLIXTLixte Biotechnology$7.51+4.2%$6.96$2.02▼$8.38$112.80M1.24506,337 shs614,310 shsRANIRani Therapeutics$0.85-4.4%$0.81$0.44▼$3.87$105.41M0.781.02 million shs1.44 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-6.35%-18.06%-39.49%-60.27%-82.12%ETHZFlag Ship Acquisition-0.53%-2.99%+12.72%+16.43%+566,999,900.00%LIXTLixte Biotechnology0.00%0.00%+9.32%+102.43%+80.96%RANIRani Therapeutics-4.39%+22.03%+10.94%-9.37%+87.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$1.18-6.3%$1.82$1.16▼$9.22$30.15M0.67465,919 shs93,394 shsETHZFlag Ship Acquisition$5.73+1.1%$5.25$0.70▼$17.46$108.94M1.176.44 million shs144,402 shsLIXTLixte Biotechnology$7.51+4.2%$6.96$2.02▼$8.38$112.80M1.24506,337 shs614,310 shsRANIRani Therapeutics$0.85-4.4%$0.81$0.44▼$3.87$105.41M0.781.02 million shs1.44 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-6.35%-18.06%-39.49%-60.27%-82.12%ETHZFlag Ship Acquisition-0.53%-2.99%+12.72%+16.43%+566,999,900.00%LIXTLixte Biotechnology0.00%0.00%+9.32%+102.43%+80.96%RANIRani Therapeutics-4.39%+22.03%+10.94%-9.37%+87.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.501,383.05% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/ALIXTLixte Biotechnology 1.00SellN/AN/ARANIRani Therapeutics 2.60Moderate Buy$8.75928.32% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ETHZ, LIXT, and RANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026ACTUActuate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/18/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.34 per shareN/AETHZFlag Ship Acquisition$4.11M26.50N/AN/A$29.12 per share0.20LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ARANIRani Therapeutics$3.17M33.26N/AN/A$0.34 per share2.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$0.97N/AN/AN/AN/A-430.93%-180.86%N/AETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/ALIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ARANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)Latest ACTU, ETHZ, LIXT, and RANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026RANIRani Therapeutics-$0.05N/AN/AN/A$0.93 millionN/A5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/14/2026Q1 2026ACTUActuate Therapeutics-$0.23-$0.24-$0.01-$0.24N/AN/A5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.801.80ETHZFlag Ship Acquisition1.1110.0710.07LIXTLixte BiotechnologyN/A2.782.78RANIRani TherapeuticsN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AETHZFlag Ship Acquisition4.07%LIXTLixte Biotechnology5.10%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%ETHZFlag Ship Acquisition15.10%LIXTLixte Biotechnology9.50%RANIRani Therapeutics26.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.93 million10.05 millionN/AETHZFlag Ship Acquisition719.01 million16.14 millionN/ALIXTLixte Biotechnology415.02 million13.59 millionNot OptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableACTU, ETHZ, LIXT, and RANI HeadlinesRecent News About These CompaniesRani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 20, 2026 | globenewswire.comRani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous DosingJuly 15, 2026 | globenewswire.comRani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle SetupJuly 14, 2026 | donanimhaber.comDRani Therapeutics Holdings Inc - Ordinary Shares Class AJuly 13, 2026 | money.usnews.comRani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidatesJuly 13, 2026 | pharmabiz.comPWhy Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?July 10, 2026 | kalkinemedia.comKRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 10, 2026 | marketbeat.comChina's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani TherapeuticsJuly 10, 2026 | yicaiglobal.comYRani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel CandidatesJuly 9, 2026 | globenewswire.comRani Therapeutics (NASDAQ:RANI) Stock Price Down 2.3% - Should You Sell?July 9, 2026 | marketbeat.comRani Therapeutics Appoints Nicholas Maestas as Chief Financial OfficerJune 29, 2026 | globenewswire.comRani Therapeutics Shareholders Back Board and Auditor at MeetingMay 29, 2026 | tipranks.comRani Therapeutics Announces $20 Million Equity FinancingMay 27, 2026 | tipranks.comRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesMay 26, 2026 | globenewswire.comRani Therapeutics Faces Nasdaq Bid Price Noncompliance NoticeMay 17, 2026 | theglobeandmail.comNasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid PriceMay 17, 2026 | tipranks.comRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionMay 15, 2026 | globenewswire.comRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comThis Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearMay 9, 2026 | finance.yahoo.comRani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14April 9, 2026 | msn.comRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyApril 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026Micron's $250 Billion Bet Could Reshape the AI Memory RaceBy Jeffrey Neal Johnson | July 10, 2026A Market Panic Just Discounted the AI Highway's TollboothBy Jeffrey Neal Johnson | July 8, 2026Fabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutBy Thomas Hughes | June 26, 2026Why the Comcast Spin-Off Won't Fix What's Actually BrokenBy Chris Markoch | July 3, 2026ACTU, ETHZ, LIXT, and RANI Company DescriptionsActuate Therapeutics NASDAQ:ACTU$1.18 -0.08 (-6.35%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.27%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Flag Ship Acquisition NASDAQ:ETHZ$5.73 +0.06 (+1.06%) As of 07/24/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Lixte Biotechnology NASDAQ:LIXT$7.51 +0.30 (+4.16%) Closing price 07/2/2026Extended Trading$7.51 0.00 (0.00%) As of 07/2/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Rani Therapeutics NASDAQ:RANI$0.85 -0.04 (-4.39%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
